Clinical management and acute exacerbations in patients with idiopathic pulmonary fibrosis in Spain: results from the OASIS study

• Published in: Respiratory research 2022-09, Vol.23 (1), p.1-235, Article 235
• Main Authors: Cano-Jiménez, Esteban, Romero Ortiz, Ana Dolores, Villar, Ana, Rodríguez-Nieto, María Jesús, Ramon, Alba, Armengol, Silvia
• Format: Article
• Language: English
• Subjects: Care and treatment; Clinical management; Development and progression; Diagnosis; Drug therapy; Early treatment; Emergency medical services; Fibrosis; Health care; Idiopathic pulmonary fibrosis (IPF); Informed consent; IPF acute exacerbations; IPF management; IPF progression; Lung diseases; Lungs; Medical prognosis; Medical records; Mortality; Patients; Pharmacology; Population; Primary care; Pulmonary fibrosis; Pulmonary functions; Quality of life; Resource utilization; Respiratory function; Sociodemographics; Variables; Variance analysis
• ISSN: 1465-993X; 1465-9921; 1465-993X; 1465-9921
• DOI: 10.1186/s12931-022-02154-y

Background Idiopathic pulmonary fibrosis (IPF) is a progressive disease associated with decline in lung function and poor prognosis entailing significant impairment in quality of life and high socioeconomic burden. The aim of this study was to characterize clinical management and resources utilization of patients with IPF in Spain, according to predicted forced vital capacity (FVC) % at baseline. Methods Prospective, non-interventional, multicentric real-world data study in patients with IPF in Spain with 12-months follow-up. Clinical management and resources utilization during study period were recorded and compared between groups. FVC decline and acute exacerbations occurrence and associated healthcare resource use were also analysed. FVC decline after 12 months was estimated as relative change. Results 204 consecutive patients with IPF were included and divided according to baseline FVC % predicted value. At baseline, patients with FVC < 50% received significantly more pharmacological and non-pharmacological treatments, and more help from caregiver. During the 12-months follow-up, patients with FVC < 50% required more specialized care visits, emergency visits, hospitalizations, pulmonary functions tests, non-health resource use (special transportation), and pharmacological treatments (p < 0.05 for all comparisons). Moreover, patients with FVC < 50% at baseline experienced more AE-IPF (p < 0.05), requiring more health-related resources use (primary care visits, p < 0.05). FVC decline was observed in all groups over the 12 months. FVC decreased on average by 2.50% (95% CI: - 5.98 to 0.98) along the year. More patients experienced an FVC decline > 10% in the more preserved lung function groups than in the FVC < 50% group, because of their already deteriorated condition. Conclusions We observed a significantly higher annual IPF-related resource use in patients with more impaired lung function at baseline. Since FVC decreases irrespective of FVC% predicted at baseline, slowing IPF progression to maintain patients at early disease stages is relevant to improve IPF management and to optimize resource use. Trial registration: EU PAS register number EUPAS19387 [June 01, 2017]. Keywords: Idiopathic pulmonary fibrosis (IPF), Clinical management, IPF acute exacerbations, IPF management, IPF progression, Early treatment